Biotech
For Avastin in breast cancer, approval is not in doubt, the only question is when. December's negative advisory panel vote was muddled and wrong, hopefully the FDA sees through that and approves the drug on Feb. 23.
If not, the disappointment is already priced in, so the risk to owning the stock is minimized. With more phase III clinical data coming later this year on the company's Rituxan drug in lupus and multiple sclerosis, and possibly Avastin in adjuvant colon cancer, it's shaping up to be a big year for successful clinical trials at Genentech. For these reasons, I expect the stock to be one of the better big-cap biotech performers in 2008.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.40 | 2,827.34 | 15.81 |
Oil *
101.86
|
|
DOWN
26.41 |
DOWN
2.92 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.22%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |
Connect with TheStreet